ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

EBS Emergent Biosolutions Inc

3.88
0.58 (17.58%)
04 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Emergent Biosolutions Inc NYSE:EBS NYSE Common Stock
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  0.58 17.58% 3.88 4.02 3.36 3.45 19,249,903 01:00:00

Emergent BioSolutions to Unveil its Expanded Center for Innovation in Advanced Development and Manufacturing Supported throug...

09/05/2017 12:00pm

GlobeNewswire Inc.


Emergent Biosolutions (NYSE:EBS)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Emergent Biosolutions Charts.

WHO:Emergent BioSolutions Inc. (NYSE:EBS) 
  
WHAT:Ribbon-cutting and tour of expanded Emergent BioSolutions’ Center for 
 Innovation in Advancement Development and Manufacturing (CIADM), 
 featuring speakers:
  
 Daniel J. Abdun-Nabi
 President & Chief Executive Officer, Emergent BioSolutions
  
 Rick A. Bright, Ph.D.
 Director, Biomedical Advanced Research and Development Authority (BARDA)
 Deputy Assistant Secretary, Office of the Assistant Secretary for Preparedness 
 and Response at the U.S. Department of Health and Human Services (HHS)
  
 William H. Cole
 President & CEO, Baltimore Development Corporation
  
 Secretary Mike Gill
 Department of Commerce, State of Maryland
  
WHY:Five years ago, Emergent and BARDA entered into a public-private partnership 
 to establish a CIADM intended to develop and manufacture medical 
 countermeasures to protect the public in health emergencies. 
  
 This Wednesday, Emergent will unveil its newly expanded Baltimore CIADM 
 facility – one of only three HHS-designated Centers in the United States. The 
 112,000-square-foot facility, comprised of laboratory, manufacturing and office 
 space, offers flexible manufacturing of drug substance from microbial, cell 
 culture, or viral production platforms. Its capabilities for advanced 
 development and manufacturing of medical countermeasures were designed to 
 help address the U.S. government’s national security and public health needs. 
 The facility is equipped with disposable manufacturing technology to enable 
 Emergent to meet the government’s domestic preparedness priorities and 
 needs on a cost-effective, reliable and sustainable basis. 
  
 Since its inception, the Emergent CIADM has been awarded four task orders by 
 BARDA to develop Ebola and Marburg therapeutics and a Zika vaccine. 
 Emergent has also successfully manufactured some of its product candidates 
 at the CIADM and an Ebola vaccine candidate as part of a third-party 
 collaboration.
  
WHERE:Emergent BioSolutions Bayview Campus
 5901 East Lombard St.
 Baltimore, MD 21224
  
WHEN:Wednesday, May 10, 2017
 9 a.m. to 11 a.m.

                       About Emergent BioSolutionsEmergent BioSolutions Inc. is a global life sciences company seeking to protect and enhance life by focusing on providing specialty products for civilian and military populations that address accidental, intentional, and naturally emerging public health threats. Through our work, we envision protecting and enhancing 50 million lives with our products by 2025. Additional information about the company may be found at www.emergentbiosolutions.com. Follow us @emergentbiosolu.

Media Contact:
Lynn Kieffer
Vice President, Corporate Communications
240-631-3391
kiefferl@ebsi.com

1 Year Emergent Biosolutions Chart

1 Year Emergent Biosolutions Chart

1 Month Emergent Biosolutions Chart

1 Month Emergent Biosolutions Chart

Your Recent History

Delayed Upgrade Clock